Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

BACKGROUND: Modern guidelines recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors as the preferred antihyperglycemic agents for patients with type 2 diabetes and chronic kidney disease. However, the mechanisms underlying the renal protective effect of SGLT2 inhibitors are not fully understoo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Diabetes
Autors principals: Klimontov, Vadim V, Korbut, Anton I, Taskaeva, Iuliia S, Bgatova, Nataliya P, Dashkin, Maksim V, Orlov, Nikolai B, Khotskina, Anna S, Zavyalov, Evgenii L, Klein, Thomas
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Inc 2020
Matèries:
Basic Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7754166/
https://ncbi.nlm.nih.gov/pubmed/33384767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v11.i12.596
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars